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I  1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA), 
and the European Commission.
In September 2017, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
acetamide, commonly known as methoxyacetylfentanyl, 
through a joint assessment based upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on methoxyacetylfentanyl satisfied criteria 4 and 
6. The two agencies therefore concluded that sufficient 
information had been accumulated to merit the production 
of a Joint Report on methoxyacetylfentanyl as stipulated by 
Article 5.1 of the Council Decision.
I  2. Information collection process
In compliance with the provisions of the Council 
Decision, on 12 October 2017 the EMCDDA and Europol 
launched a procedure for the collection of information on 
methoxyacetylfentanyl, in order to prepare the Joint Report. 
The information was collected mainly through the Reitox 
national focal points in the Member States, Turkey, Norway, 
as well as the Europol national units. In addition, the EMA 
collected information through the national competent 
authorities responsible for human and veterinary medicinal 
products in the Member States as well as in Norway, Iceland, 
and Liechtenstein. The EMA also provided information as 
relevant to the centralised procedure for authorising medicinal 
products. The information collection process was largely 
concluded by 23 November 2017.
(1) OJ L 127, 20.5.2005, p. 32. 
Information collected by Europol
Europol asked the Europol national units to provide 
information on:
 ¡ the level of production of methoxyacetylfentanyl in their 
country;
 ¡ the level of distribution of methoxyacetylfentanyl in their 
country;
 ¡ the level of trafficking of methoxyacetylfentanyl in their 
country, both for internal, transit, or export purposes;
 ¡ the number of seizures of methoxyacetylfentanyl in their 
country, the total amount of the seizures, country of origin, 
and details on the physical forms (including photos);
 ¡ the role of organised crime, or criminal groups, 
in the production, distribution, and trafficking of 
methoxyacetylfentanyl in their country; and,
 ¡ any known aspect of violence and/or money 
laundering relating to the production and trafficking of 
methoxyacetylfentanyl.
Europol received responses from 19 Member States (2) and 
Canada.
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the 
Member States, Norway, Iceland, and Liechtenstein provide 
information on whether:
 ¡ the new psychoactive substance methoxyacetylfentanyl 
has obtained a marketing authorisation;
 ¡ the new psychoactive substance methoxyacetylfentanyl is the 
subject of an application for a marketing authorisation; and,
 ¡ a marketing authorisation that had been granted in respect 
to the new psychoactive substance methoxyacetylfentanyl 
has been suspended.
Twenty five countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant 
to the centralised procedure for authorising human and 
veterinary medicinal products.
(2) In alphabetical order: Austria, Bulgaria, Cyprus, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Lithuania, 
Luxembourg, the Netherlands, Poland, Portugal, Slovenia, Spain.
(3) Austria, Belgium, Croatia, Estonia, Finland, Germany, Greece, Ireland, Italy, 
Latvia, the Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain and 
Sweden provided a response in relation to human and veterinary medicinal 
products. Cyprus, the Czech Republic, Denmark and Hungary provided 
a response in relation to human medicinal products. France, Romania and the 
United Kingdom provided a response in relation to veterinary medicinal products.
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Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
methoxyacetylfentanyl is used to manufacture a medicinal 
product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation; and,
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty five countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
 ¡ a structured questionnaire to the Reitox national focal 
points. The EMCDDA received replies from the 28 Member 
States, Turkey, and Norway;
 ¡ reports previously submitted to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms, Progress Reports, and Final Reports;
 ¡ routine monitoring of open source information;
 ¡ a specific information request to the World Health 
Organization on whether or not methoxyacetylfentanyl 
has been assessed or is under assessment by the United 
Nations system; and,
 ¡ a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’).
Thus, the information included in sections 3.2.1 and 3.3 of 
the Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 
3.5, 3.6, 3.7, 3.8.1, 3.8.2, and 3.8.3 (in part). The information 
included in section 3.8.3 (in part) and section 4 was provided 
by the EMA.
(4) Austria, Belgium, Croatia, Estonia, Finland, Germany, Greece, Ireland, Italy, 
Latvia, the Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, and 
Sweden provided a response in relation to human and veterinary medicinal 
products. Cyprus, the Czech Republic, Denmark, and Hungary provided 
a response in relation to human medicinal products. France, Romania, and the 
United Kingdom provided a response in relation to veterinary medicinal products.
I  3. Information required by Article 5.2 of the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
I  3.1 Chemical and physical description, including the names under which the new psychoactive substance is known (Article 5.2(a) of the Council Decision)
Chemical description and names
Methoxyacetylfentanyl belongs to the 4-anilidopiperidine 
class of synthetic opioids. This class also includes fentanyl 
(5), which is internationally controlled, and a number of other 
fentanils.
A total of 15 fentanils are controlled under the United Nations 
Single Convention on Narcotic Drugs, 1961, as amended by 
the 1972 Protocol (6).
Methoxyacetylfentanyl differs from fentanyl due to 
the replacement of the propionamide group with 
a 2-methoxyacetamide group. Methoxyacetylfentanyl is 
also structurally related to ocfentanil (7), which was critically 
reviewed at the 39th meeting of the Expert Committee on 
Drug Dependence (ECDD) in November 2017 (World Health 
Organisation, 2017). Methoxyacetylfentanyl differs from 
ocfentanil due to the absence of the fluorine in the 2-position 
on the phenyl ring.
The molecular structure, molecular formula, and molecular 
mass of methoxyacetylfentanyl are provided in Figure 1.
The synthesis of methoxyacetylfentanyl has been described in 
the scientific and patent literature (Huang, 1985; Jílek 1990; 
Jílek 1992).
(5) N-Phenyl-N-[1-(2-phenylethyl)piperidinyl-4-yl]propanamide
(6) 3-Methylfentanyl, 3-methylthiofentanyl, acetyl-alpha-methylfentanyl, 
alpha-methylfentanyl, alpha-methylthiofentanyl, beta-hydroxy-3-methylfentanyl, 
beta-hydroxyfentanyl, para-fluorofentanyl, thiofentanyl and acetylfentanyl are 
controlled under Schedule I and IV; alfentanil, fentanyl, sufentanil, remifentanil 
and butyrfentanyl are controlled under Schedule I.
(7) N-(2-Fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide 
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Commonly used names:  
methoxyacetylfentanyl
Systematic (IUPAC) name:  
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
acetamide
Other chemical names:  
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidyl]
acetamide;
2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-
acetamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-2-
methoxyacetamide
N-[1-(2-phenylethyl)-4-piperidinyl]-2-methoxyacetanilide
Other names and code names:  
methoxyacetyl fentanyl, methoxyacetyl-F, methoxy-AcF, 
methoxyacetyl fentanyl, desfluoro ocfentanil (Sweden)
Street names  
‘MAF’ (Belgium),  
‘methoxy’ (Belgium),  
‘synthetic heroin’ (Belgium)
Chemical Abstracts Service (CAS) registry numbers (8):  
101345-67-9 base 
101365-54-2 hydrochloride salt
(8) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
IUPAC International Chemical Identifier Key (InCHI Key) (9):  
SADNVKRDSWWFTK-UHFFFAOYSA-N
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry numbers listed above. The searches returned no 
hits.
Physical description
Methoxyacetylfentanyl contains one basic nitrogen atom in 
the piperidine ring which can readily form salts with organic or 
inorganic acids.
Limited solubility data available on methoxyacetylfentanyl 
in the hydrochloride and citrate salt forms indicates that it is 
soluble in dichloromethane, methanol, and water (Slovenian 
National Forensic Laboratory, 2016; Slovenian National 
Forensic Laboratory, 2017). Due to its similarity to fentanyl, 
the free base could be expected to be sparingly soluble in 
water.
Methoxyacetylfentanyl is expected to be lipophilic.
The measured melting point of methoxyacetylfentanyl was 
reported as 96–97°C (Jílek, 1990).
Methoxyacetylfentanyl has been detected in powders and 
liquids, and, to a lesser extent, in tablets. A more detailed 
description of seizures and collected samples can be found in 
section 3.2.1 and section 3.2.2.
(9) InChI Key is a unique, non-proprietary structural identifier of chemical 
substances useful in electronic sources.
FIGURE 1 
Molecular structure, molecular formula, and molecular mass of methoxyacetylfentanyl. Information on fentanyl and ocfentanil is 
provided for comparison.
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Detection and analysis
Methods documented in the literature for the detection 
of methoxyacetylfentanyl include: gas chromatography–
mass spectrometry (GC-MS), high performance liquid 
chromatography time-of-flight (HPLC-TOF), Fourier transform 
infrared spectroscopy attenuated total reflectance (FTIR-
ATR), gas chromatography–mass spectrometry–infrared 
spectroscopy (GC-(MS)-IR) condensed phase (Slovenian 
National Forensic Laboratory, 2016; Slovenian National 
Forensic Laboratory, 2017), and nuclear magnetic resonance 
(Slovenian National Forensic Laboratory, 2016).
There is no information on the reaction of 
methoxyacetylfentanyl to presumptive colour tests.
Methoxyacetylfentanyl is not expected to give a positive 
response to immunoassays developed for morphine-type 
opioids. It is unknown if immunoassays for fentanyl will detect 
methoxyacetylfentanyl. In addition, it is unknown whether 
such assays can distinguish between methoxyacetylfentanyl 
and fentanyl (US DEA, 2017b). Identification of 
methoxyacetylfentanyl requires confirmatory analysis (US 
DEA, 2017b).
I
  3.2 Information on the frequency, circumstances and/
or quantities in which a new psychoactive substance 
is encountered, and information on the means and 
methods of manufacture of the new psychoactive 
substance (Article 5.2(b) of the Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1 Information provided to Europol
Europol received replies from 19 Member States (Austria, 
Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, 
France, Germany, Greece, Hungary, Ireland, Lithuania, 
Luxembourg, the Netherlands, Poland, Portugal, Slovenia, and 
Spain) and Canada.
The level of production
No information was received in relation to the production of 
methoxyacetylfentanyl (10).
(10) Canada reported that there have been no clandestine laboratories seized by 
the Royal Canadian Mounted Police and no confirmed cases of trafficking related 
to methoxyacetylfentanyl. They also reported that although the level of 
distribution is unknown, Canadian-based darknet vendors offer 
methoxyacetylfentanyl for sale. 
Sweden reported that there is no known production of 
methoxyacetylfentanyl in the country. Vendors mix the 
substance in powder form with water and then they package 
the resulting solution into nasal spray bottles, ordered from 
China. This approach has been reported as characteristic for 
marketing fentanils in Sweden.
The level of distribution
Limited information was received in relation to the distribution 
(seizures) of methoxyacetylfentanyl (11) (12).
Finland reported that the level of distribution and seizures 
of methoxyacetylfentanyl in the country is considered to be 
minimal.
Slovenia reported a case of a customer who suffered severe 
poisoning following the purchase of a substance, believed 
to be methoxyacetylfentanyl. The substance was purchased 
from eurochemicalsco.com, on 2 October 2017. The analysis 
of a sample seized in relation to this case, a blue bag labelled 
as ‘CHING’, confirmed the presence of methoxyacetylfentanyl.
Sweden reported that 21 seizures of methoxyacetylfentanyl 
have been made since the substance was introduced on to 
the market. They also reported that the substance is ordered 
from Swedish websites on the surface web and sent directly 
to the end user, or, in some cases, to relatives of the user. 
There is no information to indicate that Swedish customers 
use methoxyacetylfentanyl purchased from international 
websites.
The level of trafficking
Limited information was received in relation to the trafficking 
of methoxyacetylfentanyl.
Sweden reported that the domestic postal service is used for 
the distribution of the substance which is ordered from China 
in powder form and then distributed to buyers via domestic 
postal services. There is no information to indicate that the 
substance is exported from Sweden.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from the 28 Member 
States, Turkey, and Norway. Of these, 9 Member States 
(Austria, Belgium, Denmark, France, Hungary, Latvia, Sweden, 
Slovenia, and the United Kingdom) and Norway reported 
(11) Canada reported that there has been one confirmed seizure of 10 g of 
methoxyacetylfentanyl as a white powder. The country of origin was reported as 
China and no concealment method was used. 
(12) Austria provided information on a collected sample, analysed through the 
anonymous drug checking service ‘ChEck iT!’ (section 3.2.2).
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detections of methoxyacetylfentanyl (13). Images of seizures 
and collected samples reported to the EMCDDA are provided 
in Annex 1.
It is important to note that methoxyacetylfentanyl may be 
under-detected since the substance is not routinely screened 
for. Three Member States (Belgium, Slovenia, and Sweden) 
and Norway reported that methoxyacetylfentanyl is part of 
routine screening in some (but not all) laboratories.
Seizures
In total, 33 seizure cases (14) were reported to the EMCDDA 
by 7 Member States: Belgium (1 case), Denmark (1), Hungary 
(1), Latvia (7), Sweden (20), Slovenia (1), the United Kingdom 
(1), and Norway (1). Where known, the seizures took place 
between July and October 2017 and were made by police or 
customs agencies.
Methoxyacetylfentanyl was detected in powders and 
liquids, and, to a lesser extent, in tablets. Aside from 
methoxyacetylfentanyl, no other substances were reported to 
have been detected in the seizures.
Powders
A total of 65.3 g of powder containing methoxyacetylfentanyl 
was seized in 13 cases that were reported by Belgium (1 
case), Denmark (1), Hungary (1), Latvia (6), Sweden (2), 
Slovenia (1), and the United Kingdom (1). Where known, the 
powders were reported to be white or off-white in colour. In 
one case, the powders were reported to be brown.
In 8 of the cases, the quantities seized were below 1 g. The 
largest seizure of powder was reported by Swedish customs 
and consisted of 48.9 g of substance. The seizure reported by 
Danish customs consisted of 12.7 g of powder which was sent 
from China.
In the seizure reported by Slovenia, methoxyacetylfentanyl 
was detected in a ‘legal high’ type product containing 110 
mg of powder that was labelled as ‘Ching’ (see Annex 1). The 
substance was found as its citrate salt and was purchased by 
a user from the internet.
(13) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
(14) Many ‘seizures’ relate to individual cases, however, some data provided to the 
EMCDDA are aggregated at the country level. Data is drawn from the Joint 
Report Questionnaires and data provided in the bi-annual data gathering (EU 
EWS Progress Reports and Final Reports) and from individual EMCDDA–Europol 
Reporting forms submitted to the EMCDDA on an ad hoc basis.
Liquids
A total of 271 mL of liquid containing methoxyacetylfentanyl 
was seized in 18 cases that were reported by Latvia (1 case), 
Sweden (16), and Norway (1).
Sweden reported a total of 270 mL. In the case reported by 
Latvia, the liquid was recovered from a syringe. In the case 
reported by Norway, the liquid was found in a nasal spray.
Tablets
A total of 74.5 tablets containing methoxyacetylfentanyl were 
seized in 2 cases that were reported by Sweden.
Collected samples
A total of 4 collected samples containing 
methoxyacetylfentanyl were reported by 4 Member States 
(Austria, France, Slovenia, and the United Kingdom). In all the 
cases the sample was purchased as a powder on the internet.
In 2 cases, methoxyacetylfentanyl was bought online as 
another substance. In one of these cases, reported by France, 
the user purchased the substance on the darknet as ‘fentanyl’ 
and submitted the sample for testing apparently because 
the ‘low’ price of sale elicited suspicion (EUR 17/100 mg). 
In a second case, reported by Austria, the user intended to 
purchase ‘4-HO-MET’ and received a powder containing 
4-HO-MET and methoxyacetylfentanyl.
Biological samples
Serious adverse events with confirmed exposure to 
methoxyacetylfentanyl from biological samples are discussed 
in section 3.4.2.
No other types of biological detections were reported.
I 
 3.3 Information on the involvement of organised 
crime in the manufacture or trafficking of the new 
psychoactive substance (Article 5.2(c) of the Council 
Decision)
No information concerning the involvement of organised 
crime in the manufacture and/or trafficking of the 
methoxyacetylfentanyl was reported.
Sweden reported that the availability of 
methoxyacetylfentanyl can be linked to two known vendors 
who sell substances on several domestic websites on the 
surface web. These vendors are both known to police and 
have been previously convicted of serious drug offences. It is 
reported that the vendors have contacts in China.
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Money laundering aspects
Limited information was received on money laundering 
in connection with the production and/or trafficking of 
methoxyacetylfentanyl.
Sweden reported that the known vendors for fentanils in 
the Swedish domestic market sell the substances through 
established companies and that payment is through bank 
transfer, cash on delivery, bitcoin, or Swish (15). They 
reported that money laundering is considered an element in 
those cases. In addition, the sale of fentanils in Sweden is 
considered to be very profitable due to the relatively low cost 
of purchasing and distributing the substances compared to 
the financial gains.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale, and/or trafficking 
of methoxyacetylfentanyl.
I 
 3.4 A first indication of the risks associated with the 
new psychoactive substance, including the health and 
social risks, and of the characteristics of users — 
Article 5.2(d) of the Council Decision
3.4.1 Health risks
Limited data suggests that methoxyacetylfentanyl is 
a μ-opioid receptor agonist that shares some similarities with 
opioid analgesics such as morphine and fentanyl (US DEA, 
2017a; US DEA, 2017b).
The acute effects of these types of opioids include: euphoria, 
relaxation, analgesia, sedation, bradycardia, hypothermia, and 
respiratory depression. They also have an abuse liability and 
dependence potential (Herz, 1993; Kieffer, 1999, Pasternak 
and Pan, 2013; Pattinson, 2008; Romberg et al., 2003).
Similar to other opioid analgesics, the most serious acute 
health risk from using methoxyacetylfentanyl is probably 
respiratory depression, which in overdose could lead to 
apnoea, respiratory arrest, and death (EMCDDA, 2017; 
Pattinson, 2008; White and Irvine, 1999). This risk may be 
greater due to: the difficulty in diluting the substance; a lack of 
experience with its effects and dosing; the use of other central 
nervous system depressants at the same time (such as other 
(15) Swish is a mobile app payment system which allows users to send money 
using a mobile phone connected to an online banking service. Swish is 
a payment system used between bank accounts in Sweden.
opioids, benzodiazepines, gabapentanoids, and alcohol); 
a lack of tolerance to opioids; and, using the substance alone 
(such as at home) which would make it more difficult for users 
to call for help in the case of poisoning.
Available information shows that fentanils are being sold to 
users in or as heroin or other illicit opioids, as well as used 
to make counterfeit (fake) medicines (such as fake opioid 
analgesics (‘pain killers’) and benzodiazepines). They may also 
be sold as or in other illicit drugs such as cocaine. As users will 
be unaware of this, it could increase the risk of life-threatening 
poisoning in opioid users and especially other user groups 
(such as cocaine users) who may have no existing tolerance to 
opioids
The antidote naloxone should reverse the respiratory 
depression and other features of acute poisoning caused 
by methoxyacetylfentanyl (Kim and Nelson, 2015; Ujváry 
et al., 2017). Recent clinical and community experience in 
treating poisonings caused by fentanils suggests that larger 
than normal doses and repeated doses of naloxone may 
be required to manage the poisoning in some cases; longer 
periods of observation may also be required (EMCDDA, 2017).
While there is limited data for methoxyacetylfentanyl, 
the chronic health risks might share some similarities to 
opioids such as heroin and other fentanils. This may include 
dependence.
3.4.2 Serious adverse events
Acute intoxications reported to the EMCDDA
No acute intoxications with confirmed exposure to 
methoxyacetylfentanyl were reported to the EMCDDA (16).
Deaths reported to the EMCDDA
In total, 6 deaths with confirmed exposure to 
methoxyacetylfentanyl were reported to the EMCDDA by 
Sweden. The cases occurred between December 2016 and 
June 2017.
Of the deaths, 5 were male and 1 was female. The males were 
aged between 28 and 41 years (mean 34.8, median 34); the 
age of female was 28 years. A range of other substances were 
detected in the deaths, including other central nervous system 
depressants. Other opioids were only detected in 1 case. 
In 5 cases, the individuals were found dead (two in a home 
environment).
(16) Sweden reported 3 acute intoxications with suspected exposure to 
methoxyacetylfentanyl. These cases are not discussed further in this report. 
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In 5 cases, methoxyacetylfentanyl was the cause of death or 
contributed to the death.
Serious adverse events identified in open source 
information
During 2017, more than 15 deaths associated with 
methoxyacetylfentanyl were reported in the United States 
(Beck et al., 2017; Smith and Kinkaid, 2017; US DEA, 2017b; 
Yong et al., 2017).
3.4.3 Characteristics of users
Similar to other new fentanils, methoxyacetylfentanyl is 
sold and used as a ‘legal’ substitute for illicit opioids and 
prescription opioids medicines; this may include for self-
medication, such as the alleviation of pain and/or opioid 
withdrawal. Users may include high-risk drug users as well as 
others (such as psychonauts) who may be experimenting with 
the substance.
3.4.4 Social risks
While there is limited data for methoxyacetylfentanyl, the 
social risks might share some similarities with opioids such as 
heroin and other fentanils.
Of additional note is that in the past few years fentanils 
have been sold in Europe as ready-to-use nasal sprays and 
e-liquids for vaping. In general, these novel products could 
make it easier to use such substances (with similar effects to 
injecting) and make them more socially acceptable. Further 
research is required on this topic to better understand the 
risks.
Similar to other fentanils, accidental exposure to 
methoxyacetylfentanyl may also pose a risk of poisoning. 
Those at risk may include the family and friends of users, law 
enforcement, emergency personnel, medical and forensic 
laboratory personnel, as well as those in custodial settings 
and postal services. Where required, these risks should be 
assessed and appropriate procedures, training, and protective 
measures should be implemented. This may include training in 
resuscitation and adequate provision of the antidote naloxone 
(IAB, 2017; White House National Security Council, 2017).
I 
 3.5 Information on whether or not the new substance 
is currently under assessment, or has been under 
assessment, by the UN system (Article 5.2(e) of the 
Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific, and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961, and the Convention on Psychotropic Substances, 1971.
On 22 October 2017, the World Health Organization informed 
the EMCDDA that methoxyacetylfentanyl is currently not 
under assessment and has not been under assessment by the 
UN system.
I  3.6 The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol (Article 5.2(f) of the Council Decision)
The first official EMCDDA–Europol notification of 
methoxyacetylfentanyl dates from 9 December 2016 from 
the Slovenian national focal point. The Reporting Form details 
a collected sample of 5 g of brown powder purchased from 
the Internet as part of the EU-funded project Response on 
14 November 2016. The sample was shipped from China. 
Methoxyacetylfentanyl was analytically confirmed by GC-
MS, HPLC-TOF, FTIR-ATR, FTIR-condensed phase and 
Ion Chromatography at the Slovenian National Forensic 
Laboratory in Ljubljana and by NMR at the Faculty of 
Chemistry and Chemical technology, University of Ljubljana 
(Slovenian National Forensic Laboratory, 2016).
Methoxyacetylfentanyl was added to the list of new 
psychoactive substances monitored by the EMCDDA and 
Europol through the European Union Early Warning System. 
A profile of the substance was created on the European 
Database on New Drugs (EDND). Since then, analytical 
details and other information, including a public health alert, 
have been exchanged between the EMCDDA, Europol, and 
the Member States, Turkey, and Norway on an ad hoc basis; 
the European Commission and the EMA have been kept duly 
informed.
10 / 16
JOINT REPORTS I Methoxyacetylfentanyl
I 
 3.7 Information on whether or not the new 
psychoactive substance is already subject to control 
measures at national level in a Member State 
(Article 5.2(g) of the Council Decision)
Eight Member States (Estonia, Finland, France, Ireland, Latvia, 
Lithuania, Sweden, and the United Kingdom) and Norway 
reported that methoxyacetylfentanyl is controlled under drug 
control legislation.
Five Member States (Austria, Belgium, Germany, Hungary, 
and Poland) reported that methoxyacetylfentanyl is controlled 
under specific new psychoactive substances control 
legislation.
Fifteen Member States (Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Greece, Italy, Luxembourg, Malta, the 
Netherlands, Portugal, Romania, Slovakia, Slovenia, and 
Spain) and Turkey reported that methoxyacetylfentanyl is not 
subject to control measures at the national level.
I  3.8 Further information (Article 5.2(h) of the Council Decision)
3.8.1 The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey, 
or Norway about the chemical precursors or manufacturing 
methods used to make the methoxyacetylfentanyl which has 
been detected within Europe.
Two potential precursors of fentanyl and other fentanils 
— 4-anilino-N-phenethylpiperidine (ANPP) as well as 
N-phenethyl-4-piperidone (NPP, a pre-precursor) — 
have been recently scheduled under the United Nations 
Convention against Traffic in Narcotic Drugs and Psychotropic 
Substances, 1988 (17).
The synthesis of methoxyacetylfentanyl has been described in 
the scientific and patent literature (Huang, 1985; Jílek 1990; 
Jílek 1992). Synthesis of methoxyacetylfentanyl using ANPP 
and 2-methoxyacetic anhydride (Jílek 1990; Jílek 1992), as 
well as using NPP and aniline have been documented (Huang, 
1985).
The manufacture of methoxyacetylfentanyl can also rely 
on precursors and synthetic methods similar to those 
(17) Table I of the United Nations Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988.
used for the manufacture of pharmaceutical fentanyl 
(Casy and Huckstep, 1988; Gupta et al., 2013; Zee and 
Wang, 1980). Therefore, the methods developed for the 
synthesis of fentanyl are applicable to the synthesis of 
methoxyacetylfentanyl. Use of a different acylating agent in 
the final acylation step, such as methoxyacetyl chloride would 
produce methoxyacetylfentanyl. A one-step method uses 
ANPP and methoxyacetyl chloride for the manufacture of the 
substance.
France reported that the substances aniline, NPP, ANPP, and 
methoxyacetyl chloride could be used as potential precursors 
for the synthesis of methoxyacetylfentanyl.
Most of the synthetic procedures that could be used for 
the synthesis of methoxyacetylfentanyl are straightforward 
and use common laboratory equipment and precursors. 
Detailed methods are available on the internet (18). While 
only basic knowledge of synthetic chemistry is required, 
due to the potency of fentanils extreme caution is required 
when carrying out the final synthetic step as well as when 
purifying and handling the substance. Exposure of the skin 
and mucous membranes to fentanils as well as their inhalation 
pose a serious risk of accidental poisoning. In addition to 
exercising extreme caution, suitable personal protective 
equipment as well as sufficient stocks of naloxone as an 
antidote to poisoning following accidental exposure should 
be available when handling materials suspected to contain 
these substances (IAB, 2017; White House National Security 
Council, 2017).
In summary, the synthesis of methoxyacetylfentanyl has been 
described in the literature. In addition, other routes developed 
for the manufacture of fentanyl may also be used. There is no 
information on the actual method(s) used for the production 
of methoxyacetylfentanyl that has been detected in Europe to 
date.
3.8.2 The mode and scope of the established 
or expected use of the new substance
No studies were identified that have examined the 
mode and scope of established or expected use of 
methoxyacetylfentanyl. Given the limited information currently 
available, the relevant information has been included in the 
previous sections.
(18) The detailed description of the most common procedure, referred to as the 
‘Siegfried method’, is readily available on the internet (see, for example, http://
opioids.com/fentanyl/synthesis.html).
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3.8.3 Other use of the new psychoactive substance 
and the extent of such use, the risks associated with 
this use of the new psychoactive substance, including 
the health and social risks
No information was provided by the Member States, Turkey, 
or Norway that indicated that methoxyacetylfentanyl had any 
other use apart from in analytical reference materials and 
scientific research.
From the available information, it does not appear that 
methoxyacetylfentanyl is used in the manufacture of 
a medicinal product in the European Union. However, the 
data collection is incomplete and some countries indicated 
that this information is not known. It is understood that the 
collection of such information is a challenge in the absence of 
a database on the synthetic route of all medicinal products.
Ten countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Finland, Germany, Greece, Latvia, and the 
Netherlands) reported that methoxyacetylfentanyl is not used 
to manufacture a medicinal product for human use. Twelve 
countries (Cyprus, Estonia, Hungary, Ireland, Italy, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, and Sweden) 
reported that it was unknown if methoxyacetylfentanyl is used 
to manufacture a medicinal product for human use.
In addition, the EMA reported that it is not known if 
methoxyacetylfentanyl is used in the manufacture of 
medicinal products for human use and which are centrally 
authorised within the European Union.
Ten countries (Austria, Belgium, Croatia, Finland, France, 
Greece, Latvia, Poland, Romania, and the United Kingdom) 
provided information that methoxyacetylfentanyl is not used 
to manufacture a medicinal product for veterinary use. Eleven 
countries (Estonia, Germany, Ireland, Italy, the Netherlands, 
Norway, Portugal, Slovakia, Slovenia, Spain, and Sweden) 
reported that it was unknown if methoxyacetylfentanyl is used 
to manufacture a medicinal product for veterinary use.
In addition, the EMA reported that it is not known if 
methoxyacetylfentanyl is used in the manufacture of 
medicinal products for veterinary use and which are centrally 
authorised within the European Union.
I  4. Information from the EMA (Article 5.3 of the Council Decision)
Twenty-two countries (Austria, Belgium, Croatia, Cyprus, 
Czech Republic, Denmark, Estonia, Finland, Germany, Greece, 
Hungary, Ireland, Italy, Latvia, the Netherlands, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, and Sweden) 
reported that:
 ¡ methoxyacetylfentanyl has not been granted a marketing 
authorisation as a medicinal product for human use;
 ¡ methoxyacetylfentanyl is not the subject of an application 
for a marketing authorisation as a medicinal product for 
human use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to methoxyacetylfentanyl as 
a human medicine.
Twenty-one countries (Austria, Belgium, Croatia, Estonia, 
Finland, France, Germany, Greece, Ireland, Italy, Latvia, the 
Netherlands, Norway, Poland, Portugal, Romania, Slovakia, 
Slovenia, Spain, Sweden, and the United Kingdom) reported 
that:
 ¡ methoxyacetylfentanyl has not been granted a marketing 
authorisation as a medicinal product for veterinary use;
 ¡ methoxyacetylfentanyl is not the subject of an application 
for a marketing authorisation as a medicinal product for 
veterinary use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to methoxyacetylfentanyl as 
a veterinary medicine.
The EMA also reported that methoxyacetylfentanyl:
 ¡ has not been granted a marketing authorisation as 
a medicinal product for neither human nor veterinary use 
through the centralised procedure;
 ¡ is not the subject of an application for a marketing 
authorisation for neither human nor veterinary use through 
the centralised procedure;
 ¡ is not the subject of a suspended marketing authorisation 
for neither human nor veterinary use through the 
centralised procedure.
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I 5. Conclusion
Methoxyacetylfentanyl belongs to a group of synthetic 
opioids known as the fentanils. It is closely related to 
fentanyl, which is controlled under the United Nations Single 
Convention on Narcotic Drugs, 1961. Data suggests that 
methoxyacetylfentanyl may be an opioid narcotic analgesic 
in humans, and, as such, may have an abuse liability and 
dependence potential; overall, these effects may be broadly 
comparable to fentanyl. The most serious acute health risk 
posed by methoxyacetylfentanyl is likely to be respiratory 
depression, which in overdose is life-threatening. The antidote 
naloxone should reverse this respiratory depression.
Methoxyacetylfentanyl has been available in the European 
Union since at least November 2016. It has been detected 
in 9 Member States and Norway where it has been seized 
as a powder, liquids, and tablets. The detected quantities 
are relatively small; however, they should be seen within the 
context of the high potency that is typical of the fentanils.
There are indications that the methoxyacetylfentanyl currently 
available on the market is synthesised by chemical companies 
based in China. Methoxyacetylfentanyl is sold online often 
under the guise of a ‘research chemical’. It is offered in 
wholesale amounts and in consumer amounts.
Six deaths with confirmed exposure to methoxyacetylfentanyl 
have been reported by Sweden. In at least 5 of the deaths, 
methoxyacetylfentanyl was the cause of death or contributed 
to the death.
Methoxyacetylfentanyl is sold and used as a substitute 
for illicit opioids and prescription opioids. Similar to other 
fentanils, serious concerns exist that the substance could be 
supplied surreptitiously to a range of drug users.
Methoxyacetylfentanyl has not been assessed within the 
United Nations system nor is it currently under assessment. 
Methoxyacetylfentanyl is not subject to control measures in 
15 Member States and Turkey.
Methoxyacetylfentanyl does not appear to have any 
recognised human or veterinary medical use in the European 
Union.
We conclude that the health and social risks caused by the 
manufacture, trafficking, and use of methoxyacetylfentanyl, 
as well as the involvement of organised crime and possible 
consequences of control measures, could be thoroughly 
assessed through a risk assessment procedure in accordance 
with Article 6 of Council Decision 2005/387/JHA.
The EMCDDA and Europol will continue to intensively 
monitor methoxyacetylfentanyl in order to ensure that new 
information is provided to the Member States, the EMA, and 
the Commission via the information exchange of the European 
Union Early Warning System.
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I  Annex 1  Images from seizures and collected samples provided to the EMCDDA
Country Image Description
Slovenia Seizure
Date: 10 November 2017
Seizing authority: Police
Ordered from a website for ‘personal use’
United Kingdom Collected sample
Date: 29 March 2017
Collecting authority: TICTAC Communications Ltd.
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